|
|
|
|
|
|
|
 |
You are here : Home > People & Partners > Scientific Advisory Board Our scientific advisors - helping us in discovery and developmentMeetings of our scientific advisors are formally chaired by David Horwell, who works closely with David Scopes and the scientific team to help Senexis progress its pipeline through drug discovery and into clinical development. Dr David Horwell Royal Society of Chemistry linkDavid Horwell graduated from London University before undertaking his PhD in organic heterocyclic chemistry at Leicester University with Professor C W Rees, CBE, FRS. He then carried out post-doctoral research in Canada (National Research Council, Ottawa), Florida (Gainesville) and at Imperial College, London. This was followed by a research career in the pharmaceutical industry with Eli Lily, Parke-Davis/Warner-Lambert and Pfizer. He was a Visiting Professor at University of East Anglia for over 10 years before being appointed to the Chair of Medicinal Chemistry from 2001 to 2006. David is now an independent consultant. Professor Andrew Doig University of Manchester linkAndrew graduated in Chemistry from the University of Cambridge, where he stayed to complete his PhD on protein folding and peptide binding with Professor Dudley Williams, FRS, in 1991. He then carried out post-doctoral research in the Biochemistry Department at Stanford with Professor Robert Baldwin before joining UMIST in 1994. He is now a Professor of Biochemistry in the Faculty of Life Sciences at the University of Manchester. In addition to being an expert on protein structure, Andrew was a founder of Senexis with and continues to collaborate with Senexis. Professor Dominic Walsh University College Dublin linkDominic obtained his Ph.D. in Veterinary Science from the Queen's University Belfast, where he stayed as a postdoctoral research fellow before leaving for Harvard in 1995 to work with Prof. Dennis Selkoe. In 2003, Dominic became a Wellcome Trust Senior Research Lecturer at University College Dublin, where he has now been an Associate Professor of Biochemistry since 2006. His research has recently focused on demonstrating the key finding that the toxic forms of beta-amyloid are stable, soluble oligomers. Professor Nancy Rothwell University of Manchester link Professor Nancy Rothwell is the MRC Research Professor and Vice-President for Research at The University of Manchester. Nancy obtained her BSc, PhD and DSc in Physiology from the University of London. She was a awarded a Royal Society Research Fellowship and subsequently moved to the University of Manchester where she was promoted to a chair in Physiology in 1994. Over the last decade her research has been trying to understand the processes which lead to brain damage in diseases such as stroke and in brain trauma. This research spans from basic laboratory studies to clinical research in patients and involves a number of collaborative projects with industry. She has trained almost 40 PhD students and plays a major role in the training of young scientists. Nancy is a member of BBSRC Council and was until recently chairman of the MRC Neuroscience Board, President of the British Neuroscience Association and a Council member of The Academy of Medical Sciences. She is a trustee of Cancer Research UK and the Chair of the Wellcome Trust Public Engagement Strategy panel. In 2005, Nancy became a Dame Commander of the Order of the British Empire in the Queen's Birthday Honours List. Dr Harry Levine, III University of Kentucky linkHarry obtained his B.S. in Biochemistry from Cornell University and his Ph.D. in Physiological Chemistry from Johns Hopkins University School of Medicine in 1975. After 28 years of research and drug discovery in the pharmaceutical industry at Burroughs-Wellcome, Glaxo, Parke-Davis and Pfizer, Harry joined the Center on Aging in the Department of Molecular & Cellular Biochemistry at the University of Kentucky, where he is an Associate Professor. Dr Ann Hayes, Director of The Ann Hayes Consultancy LtdAnn worked for 22 years for GlaxoWellcome, initially in research, with particular expertise in the areas of CNS and pain. Before the GSK merger, she was a Director in Drug Discovery, and was involved in determining long-term Discovery strategy, in portfolio management and in discovery project management. Ann left GSK in 2001 and set up a business as an independent pharmaceutical consultant. In this capacity she has co-founded three companies, Ionix Pharmaceuticals which has been bought by Vernalis, Therasci which has been bought by CeNeS, and Theradeas. Ann is a non-executive director for Curidium Medica plc and Plethora Solutions plc, and a member of the advisory boards for CeNeS, Bionomics and Lectus. She has also held NED positions at Therasci, Ionix and Sirus (which was sold to Arakis). She currently consults regularly for CeNes and Shire, as well as doing ad hoc consulting for a number of small companies and VCs. In addition, to advising Senexis directly, Ann also acts as the independent consultant on the Research Steering Group of the research programme currently funded by the Wellcome Trust.
|
